Dyno Therapeutics is reshaping the gene therapy landscape with AI-powered AAV vectors

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Eric Kelsic
  • Alan Crane
  • Sam Simai
  • Adrian Veres
  • George Church
  • Tomas Bjorklund

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • Come join our first Agile in Biotech MeetUp - a forum where those of us interested in experimenting with Agile appr… https://t.co/VU6AeMkFgL@Dyno_Tx - 01:34 PM Jun 8th
  • #BIO2022 is almost here! Meet up with our team during the conference to learn more about our machine-guided approac… https://t.co/oVuqKrkWsC@Dyno_Tx - 01:09 PM Jun 6th
  • Reminder: Our team is hosting a symposium tomorrow from 12-1:30 PM in Room 202 on how we are transforming the gene… https://t.co/pDbAbDZAmw@Dyno_Tx - 11:24 AM May 17th